Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Aptinyx brings in $65mm via Series A round

Executive Summary

Aptinyx Inc. (N-methyl-D-aspartic acid (NMDA) receptor modulators for neurological disorders) raised $65mm in a Series A round led by New Leaf Venture Partners, which was joined by other new backers Frazier Healthcare Partners, Longitude Capital, and Osage University Partners; other participants included returning seed investors Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O'Keefe & Co., and Northwestern University. New Leaf, Frazier, and Longitude added members to the board.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register